University of Calgary
Welcome,         Profile    Billing    Logout  
 450 Trials 
554 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Woods, Scott
NCT04262401: Promoting Healthy Habits in Metabolic Syndrome

Recruiting
N/A
424
US
Standard health coaching, Habit-focused health coaching
Habit Design, University of Washington, TriHealth Inc.
Metabolic Syndrome
04/24
12/24
Gerstein, Hertzel
REMITiDegLira, NCT03862716: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

Completed
3
159
Canada
IDegLira, insulin degludec / liraglutide, insulin degludec, Metformin, Lifestyle Therapy, diet and exercise
Population Health Research Institute, Novo Nordisk A/S
Type 2 Diabetes Mellitus
06/22
07/23
Gillis, Anne M
RASTA AF, NCT03682991: Reversal of Atrial Substrate to Prevent Atrial

Recruiting
N/A
670
Canada
Aggressive Risk Factor Control, Standard of Care
Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), Abbott, Phillips, Cardiac Arrhythmia Network of Canada
Atrial Fibrillation
06/25
06/27
Exner, Derek V
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
ALERT, NCT05821465: Ambulatory Leadless Electrocardiogram Recorder Trial Feasibility

Completed
N/A
144
Canada
HeartWatch
HelpWear Inc.
Arrhythmias, Cardiac, Palpitation, Syncope, Light Headedness
07/24
07/24
Cowie, Robert
CanCOLD, NCT00920348: The Canadian Cohort Obstructive Lung Disease

Active, not recruiting
N/A
1500
Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Takeda, Merck Sharp & Dohme LLC, Almirall, SAS
COPD, Chronic Obstructive Pulmonary Disease
12/22
12/22
Sigal, Ronald J
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease

Recruiting
3
150
Canada, US
Sotagliflozin, INPEFA, Placebo
Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
12/28
05/29
Kennedy, Sidney H
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
Raj, Satish
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry

Recruiting
N/A
1000
Europe, Canada, US, RoW
Defibrillation using EV-ICD
Medtronic
Ventricular Arrhythmia, Tachycardia
05/30
10/37
Anderson, Craig
OPTIMISTmain, NCT03734640 / ACTRN12619001556134: Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Recruiting
N/A
7200
Europe, US, RoW
Low-intensity monitoring strategy, Guideline recommended standard monitoring
Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia
Acute Ischemic Stroke Patients Receiving Reperfusion Therapy
11/24
03/25
Hill, Michael D
PLATINUM, NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Terminated
4
115
US
Patiromer Powder for Oral Suspension [Veltassa], Active drug, Placebo, Inactive substance
Comprehensive Research Associates
Hyperkalemia
03/23
06/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
NCT05123755: Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Recruiting
2a
120
US
AV-001 Injection, AV-001 Placebo Injection
Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
12/24
03/25
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
RAISE, NCT06226805: Study of BB-031 in Acute Ischemic Stroke Patients

Recruiting
2
156
US, RoW
BB-031, DTRI-031, Placebo, Saline
Basking Biosciences, Inc.
Acute Ischemic Stroke
12/26
03/27
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT06403267: NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy

Recruiting
2
600
Canada
NoNO-42, Placebo, Control
NoNO Inc.
Acute Ischemic Stroke
05/26
05/26
Howlett, Jonathan G
REVAD, NCT03356353: Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation

Recruiting
3
24
Canada
Sildenafil Citrate, Revatio
University of Calgary, Pfizer
End Stage Heart Failure
09/21
01/22
Graham, Karen A
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Recruiting
2
75
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
03/25
08/25
Kavanagh, Katherine
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
Friedrich, Matthias
NCT05180240 / 2021-006637-19: Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Active, not recruiting
2
109
Europe, Canada, US, RoW
CardiolRx, Cannabidiol
Cardiol Therapeutics Inc., Cardiol Therapeutics Inc.
Acute Myocarditis
01/25
02/25
Louie, Thomas
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
NCT03988855: An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Recruiting
2
40
Canada, US
DNV3837
Deinove
Clostridium Difficile (C. Difficile)
12/22
12/22
NCT04121169: Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

Recruiting
2
60
Canada
IM-01, Chicken egg-derived anti-C.difficile polyclonal antibodies
ImmuniMed Inc., University of Calgary, University of Manitoba
Clostridium Difficile Infection (CDI)
12/23
03/24
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Active, not recruiting
2
108
Canada, US
CRS3123, Active Comparator
Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
02/24
04/24
Tremblay, Alain
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/24
12/26
Anderson, John
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
03/26
12/28
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
HAErmony-1, NCT05121376 / 2021-003603-18: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Active, not recruiting
1/2
44
Europe, US, RoW
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc.
Hereditary Angioedema, HAE
11/28
11/28
NCT04296903: Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)

Active, not recruiting
N/A
200
US
MID-C System
Apifix
Adolescent Idiopathic Scoliosis
06/29
06/30
NCT04770870: Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

Recruiting
N/A
232
US
Hintermann Series H3 Total Ankle Replacement System
DT MedTech, LLC
Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
04/29
04/29
Taylor, Valerie
MELO, NCT05252598: Mood and Cognitive Effects of Psilocybin in Healthy Participants

Withdrawn
1
20
NA
Psilocybin, Melocin, Inonotus Obliquus Whole Extract, Chaga
Optimi Health Corporation, University of Calgary
Mood Disturbance, Mood Change, Sleep Disturbance, Drug Effect, Psychedelic Experiences, Health, Subjective, Psilocin Toxicity, Psilocybin Toxicity, Psilocybin Causing Adverse Effects in Therapeutic Use, Anxiety
08/23
12/23
Reimer, Raylene A
NCT03042494: Effect of Prebiotic Intake on Gut Microbiota in Healthy Adults

Completed
N/A
50
Canada
Control, Prebiotic
University of Calgary, General Mills
Healthy
05/17
12/22
NCT06300060: Synbiotic Supplementation in Cyclists

Active, not recruiting
N/A
36
Canada
Synbiotic, Placebo
University of Calgary, Lallemand Health Solutions
Exercise Endurance
12/24
12/24
Walsh, Michael
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Calendar Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease
Recruiting
3
2000
Europe, Canada, RoW
Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo
The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
06/27
12/27
NCT04984291: Zimmer Biomet Shoulder Arthroplasty PMCF

Recruiting
N/A
584
Japan, US, RoW
Alliance Glenoid, Alliance, Identity Stem, Identity
Zimmer Biomet
Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain
08/33
08/33
Har, Bryan J
DTU-STEMI, NCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: the STEMI-DTU Trial

Active, not recruiting
N/A
527
Europe, Canada, US
Impella CP® placement prior to reperfusion with Primary PCI
Abiomed Inc.
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
09/24
10/30
Wills, Anne-Marie A
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT05956834: A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes

Recruiting
N/A
60
US
PAMSys, LEGSys
Massachusetts General Hospital, Johns Hopkins University, BioSensics
PSP, CBD, Progressive Supranuclear Palsy, FTD, Corticobasal Degeneration, Frontotemporal Dementia, Frontotemporal Lobar Degeneration
12/25
12/26
Thomalla, Götz
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
DISTAL, NCT05029414: EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

Active, not recruiting
N/A
543
Europe, RoW
Endovascular Therapy
University Hospital, Basel, Switzerland, Swiss National Fund for Scientific Research, Stryker Neurovascular, Penumbra Inc., Medtronic, Phenox GmbH, Rapid Medical, Gottfried und Julia Bangerter-Rhyner-Stiftung
Acute Ischemic Stroke
10/24
06/25
ASSISTENT, NCT03902444: AcandiS Stenting of Intracranial STENosis - regisTry

Recruiting
N/A
150
Europe
Credo® Stent, NeuroSpeed® PTA balloon catheter
Acandis GmbH
Intracranial Stenosis
03/25
10/25
Andrews, Christopher N
NCT06317441: The Safety and Efficacy of a Probiotic Intervention on SIBO and Related Gastrointestinal Symptoms

Recruiting
N/A
105
Canada
Probiotic
Nimble Science Ltd., Lallemand Health Solutions
Small Intestinal Bacterial Overgrowth, SIBO
12/25
12/25
Bhutani, Mohit
TERAA, NCT06705764: Tezepelumab in the Treatment of Emergency Room Asthma in Adults

Not yet recruiting
4
100
Canada
Tezepelumab, Placebo
University of Alberta, AstraZeneca
Severe Asthma
11/25
11/26
Leigh, Richard
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
NCT04672291: Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults

Completed
1
43
Canada
Poly-ICLC (Hiltonol®) or Placebo, Safety, Expansion
Oncovir, Inc., University of Calgary
COVID - 19
04/23
04/23
NCT06592768: A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma

Recruiting
1
30
Canada
Briquilimab, JSP191, Placebo Comparator
Jasper Therapeutics, Inc.
Allergic Asthma
03/25
09/25
PASTS, NCT06084052: Path Active Multicentre Randomised Controlled Trial (Previous Pilot: Path Active; Safety and Tolerability Study)

Recruiting
N/A
120
Europe
Path Active, Control Group
Royal Free Hospital NHS Foundation Trust, Walk With Path
Diabetic Foot
12/24
02/25
Arnold, Paul
NCT05329129: OssDsign® Spine Registry Study ("Propel")

Recruiting
N/A
300
US
OssDsign® Catalyst
OssDsign
Degenerative Disc Disease, Spinal Stenosis
03/27
04/27
Swain, Mark
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
Coffin, Carla
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
NCT05330455: Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Recruiting
2
132
Europe, Canada, RoW
GSK3965193, Placebo to match GSK3965193, Bepirovirsen
GlaxoSmithKline
Hepatitis B
10/27
10/27
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

Recruiting
2
450
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Hepatitis B
02/29
02/29
Demchuk, Andrew
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Recruiting
3
860
Europe, Canada, Japan, US
Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo
Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage
01/28
01/28
Wilton, Stephen
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Terminated
3
1238
Canada
Rivaroxaban, Xarelto, standard of care
Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation
ATRIAL FIBRILLATION
05/24
05/24
RASTA AF, NCT03682991: Reversal of Atrial Substrate to Prevent Atrial

Recruiting
N/A
670
Canada
Aggressive Risk Factor Control, Standard of Care
Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), Abbott, Phillips, Cardiac Arrhythmia Network of Canada
Atrial Fibrillation
06/25
06/27
RAPID AFib, NCT05900414: Pilot Study of the Decision Aid for Stroke Prevention in Atrial Fibrillation

Not yet recruiting
N/A
60
NA
Electronic patient decision aid, Information
University of Calgary, Servier
Atrial Fibrillation
03/25
03/25
LAAOS-4, NCT05963698: The Fourth Left Atrial Appendage Occlusion Study

Recruiting
N/A
4000
Europe, Canada, US
WATCHMAN device
Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation
Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
09/29
12/29
Korngut, Lawrence M
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27
Quinn, Russell
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
CATCH, NCT06164808: Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch

Active, not recruiting
N/A
205
Canada
HeartWatch
HelpWear Inc.
Cardiac Arrhythmia, Diagnostic/Monitoring Devices Related to Adverse Incidents
07/24
10/24
ALERT, NCT05821465: Ambulatory Leadless Electrocardiogram Recorder Trial Feasibility

Completed
N/A
144
Canada
HeartWatch
HelpWear Inc.
Arrhythmias, Cardiac, Palpitation, Syncope, Light Headedness
07/24
07/24
Maragakis, Nicholas M
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting
3
150
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
Martinez, Jose M
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
Sumner, Glen
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
Guenette, Jordan A
HOPE-IPF, NCT02551068: High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Recruiting
N/A
88
Canada
60% Oxygen, Standard of Care
University of British Columbia, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
12/26
12/26
Kent, Michael
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
Stickland, Michael
NCT03679312: The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD

Completed
1/2
140
Canada
Nitric Oxide, Inhaled Nitric Oxide, Placebo, Medical Grade Room Air
University of Alberta, University Hospital Foundation, Canadian Lung Association, Canadian Institutes of Health Research (CIHR)
Dyspnea
11/23
11/23
NCT04966637: Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data

Completed
N/A
54028
Canada
COPD cohort
University of Alberta, Boehringer Ingelheim, Alberta Health services
Chronic Obstructive Pulmonary Disease (COPD
10/22
11/24
HOPE-IPF, NCT02551068: High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Recruiting
N/A
88
Canada
60% Oxygen, Standard of Care
University of British Columbia, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
12/26
12/26
Smith, Eric L
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
ATTENTION-AD, NCT04314934: OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

Completed
2/3
300
Europe, Canada, RoW
ANAVEX2-73, Blarcamesine
Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH
Alzheimer Disease
06/24
06/24
LX2020-01, NCT06109181: Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Recruiting
1/2
10
US
LX2020
Lexeo Therapeutics
Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
02/26
02/27
NCT00966979: Triathlon® Partial Knee Replacement (PKR) Outcomes Study

Terminated
N/A
111
Europe, US
Triathlon PKR
Stryker Orthopaedics
Arthroplasty, Replacement, Knee
09/22
05/23
COMPASS-ND, NCT03402919: Comprehensive Assessment of Neurodegeneration and Dementia

Recruiting
N/A
2300
Canada
McGill University, Canadian Institutes of Health Research (CIHR), Alzheimer Society of Canada, Sanofi, New Brunswick Health Research Foundation, Saskatchewan Health Research Foundation, Women's Brain Health Initiative, Michael Smith Foundation for Health Research, Alzheimer's Research UK, Alberta Prion Research Institute, Nova Scotia Health Research Foundation, Eli Lilly and Company, Canadian Nurses Foundation (CNF), Ontario Brain Institute, Consortium pour l'Identification precoce du Maladie Alzheimer du Quebec, Pfizer, Canadian Consortium on Neurodegeneration in Aging
Dementia
09/23
09/23
NCT05721859: M-Vizion™ Macroscopic Radiographic Study

Recruiting
N/A
70
US
revision hip arthroplasty
Medacta USA
Revision Hip Arthroplasty
06/25
06/25
Wyse, George
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
Gallegos-Orozco, Juan
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
FRESH, NCT05639543 / 2022-001639-10: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Alcohol Associated Hepatitis
12/24
03/25
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
 

Download Options